Novartis AG

NOVN

CH0012005267

Pharmaceuticals

Market Closed - Swiss Exchange Other stock markets 11:30:51 2024-04-16 am EDT			5-day change	1st Jan Change
85 ^CHF	-1.73%		-1.59%	+0.15%

07:28am	Novartis reports positive interim results for Fabhalta	CF
05:26am	Novartis' Investigational Kidney Disease Drug Shows Reduced Disease Marker in Late-stage Trial	MT

NOVARTIS AG : JP Morgan remains a Sell rating

July 06, 2021 at 05:22 am EDT

The analyst from JP Morgan, Richard Vosser, maintains his advice to sell. The target price continues to be set at CHF 80.

Latest news about Novartis AG

Novartis reports positive interim results for Fabhalta	01:28am	CF
Novartis' Investigational Kidney Disease Drug Shows Reduced Disease Marker in Late-stage Trial	11:26pm	MT
Health Care Ticks Down Amid Rotation From Rate-Sensitive Sectors -- Health Care Roundup	Apr. 15	DJ
Novartis' Fabhalta Found to Lower Disease Marker in Kidney Disease Patients	Apr. 15	MT
Novartis Gets Priority Review for Kidney Disease Treatment	Apr. 15	DJ
New Novartis Fabhalta(R) (iptacopan) data show clinically meaningful and statistically significant proteinuria reduction of 38.3% versus placebo for patients with IgA nephropathy (IgAN)	Apr. 15	DJ
Novartis Secures Exclusive Licensing Deal with Arvinas for Prostate Cancer Drug	Apr. 12	MT
Health Care Slips on Risk Bias -- Health Care Roundup	Apr. 11	DJ
Trending : Novartis Begins Tender Offer for MorphoSys Shares	Apr. 11	DJ
Novartis: licensing agreement in prostate cancer	Apr. 11	CF
Novartis: MorphoSys Board recommends tender offer	Apr. 11	CF
MorphoSys Board Supports Norvartis' Buyout Offer as Tender Period Begins	Apr. 11	MT
Morphosys management bodies recommend acceptance of Novartis takeover bid	Apr. 11	DP
Arvinas Agrees to License Prostate Cancer Treatment, Sell AR-V7 Program to Novartis	Apr. 11	MT
Arvinas, Novartis in ARV-766 Prostate Cancer License Pact	Apr. 11	DJ
Novartis licenses Arvinas' cancer drug for up to $1 billion	Apr. 11	RE
Arvinas, Inc Enters into an Exclusive Strategic License Agreement with Novartis AG for the Development and Commercialization of Protac Androgen Receptor Protein Degrader Arv-766 for the Treatment of Prostate Cancer	Apr. 11	CI
Novartis begins tender offer for cancer-focused MorphoSys	Apr. 11	RE
NOVARTIS : UBS reiterates its recommendation on the stock	Apr. 11	CF
Novartis Launches Tender Offer for Germany's MorphoSys	Apr. 11	MT
Novartis initiates tender offer for MorphoSys	Apr. 11	CF
Novartis begins tender offer for cancer-focused MorphoSys	Apr. 11	RE
Dpa-AFX Overview: COMPANIES from 10.04.2024 - 15:15	Apr. 10	DP
NOVARTIS AG : UBS remains its Buy rating	Apr. 10	ZD
Factbox-European companies cut jobs as economy sputters	Apr. 10	RE

Novartis AG is one of the world's leaders in the design, manufacturing, and marketing of pharmaceutical products. Net sales (excluding discontinued operations) break down by therapeutic area as follows: - oncology (29.9%); - immunology (17.2%); - cardiovascular, renal and metabolic diseases (14.1%); - neuroscience (8.9%). The remaining net sales (29.9%) are from contract manufacturing of pharmaceutical products. At the end of 2023, Novartis AG had 33 production sites worldwide. Net sales are distributed geographically as follows: Europe (33%), the United States (39.5%), Asia/Africa/Australasia (20.5%), Canada and Latin America (7%).

Sector

Pharmaceuticals

Calendar

2024-04-23 - Q1 2024 Earnings Release

Related indices

SMI , STOXX EUROPE 600 (EUR)

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

NOVARTIS : Novartis on course to set new highs

February 20, 2024 at 11:30 am EST

Novartis AG : Sandoz takes its first steps on the stock exchange

October 04, 2023 at 10:32 am EDT

More Strategies

Ratings for Novartis AG

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

94.7 USD

Average target price

107.5 USD

Spread / Average Target

+13.51%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
NOVARTIS AG	+0.15%	207B
ELI LILLY AND COMPANY	+28.04%	676B
NOVO NORDISK A/S	+24.27%	559B
JOHNSON & JOHNSON	-7.38%	356B
MERCK & CO., INC.	+15.30%	320B
ABBVIE INC.	+5.45%	286B
ASTRAZENECA PLC	+2.62%	213B
ROCHE HOLDING AG	-9.41%	199B
AMGEN INC.	-8.02%	142B
SANOFI	-3.31%	116B

Other Pharmaceuticals

Novartis AG

Equities

NOVN

CH0012005267

Pharmaceuticals

NOVARTIS AG : JP Morgan remains a Sell rating

Latest news about Novartis AG

Chart Novartis AG

Company Profile

Income Statement Evolution

Analysis / Opinion

Ratings for Novartis AG

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Pharmaceuticals